corporate_fare

Mediar Therapeutics Inc.

Address: 20 Overland Street Suite 520

Sponsor Overview

assignment

Specializations

Respiratory Medicine

Mediar Therapeutics Inc. focuses on clinical research in idiopathic pulmonary fibrosis, a chronic interstitial lung disease marked by progressive scarring of the lungs and declining respiratory function.

Forced vital capacity
Lung fibrosis
Pulmonary function

The sponsor’s research activity is centered on outcomes relevant to breathing capacity and the preservation of lung function in people living with fibrotic lung disease.

Fibrotic Lung Disease

The clinical portfolio includes investigation of therapies directed at pulmonary fibrosis, with attention to disease progression and structural changes in the lung tissue.

Progressive fibrosis
Respiratory impairment
Interstitial lung pathology

Research in this area addresses the therapeutic needs of patients affected by chronic fibrosing conditions that compromise gas exchange and physical endurance.

Pulmonary Function Assessment

Mediar Therapeutics Inc. includes clinical evaluation of measures used to track pulmonary health, especially changes in forced vital capacity as an indicator of respiratory status.

Respiratory physiology
Breathing mechanics
Clinical lung assessment

This area reflects an interest in functional endpoints that capture the impact of treatment on everyday respiratory performance.

Rare Disease Therapeutics

The sponsor’s research is directed toward a serious and uncommon chronic lung disorder with limited treatment options, placing emphasis on unmet needs in orphan respiratory disease care.

Unmet medical need
Chronic progressive disease
Specialty pulmonary care

Its clinical activity is concentrated on therapeutic development for patients with advanced fibrotic lung disease across multiple collaborating research sites.

Trial Name	Country	Status
Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of MTX-463 Efficacy and Safety in Idiopathic Pulmonary Fibrosis Patients	Belgium Croatia France Ireland Spain The Netherlands	Recruiting
Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study of IV MTX‑474 for Safety and Efficacy in Diffuse Cutaneous Systemic Sclerosis (dcSSc)	France Italy Poland Romania Spain The Netherlands	Not Yet Recruiting